RAM
ZVRA icon

Readystate Asset Management’s Zevra Therapeutics ZVRA Stock Holding History

Readystate Asset Management’s Portfolio ZVRA Stock Details ZVRA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q3 		– Sell
-111,515
Closed -$982K – 733
2025
Q2 		$982K Sell
111,515
-571,517
-84% -$4.64M 0.03% 213
2025
Q1 		$5.12M Buy
683,032
+616,370
+925% +$4.9M 0.17% 94
2024
Q4 		$556K Buy
+66,662
New +$569K 0.02% 464

Other funds holding ZVRA

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
WP
Woodline Partners San Francisco, California $32.4B AUM 58.5% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $71.3B AUM 56.8% 1-Year Est. Return
NCM
Nantahala Capital Management New Canaan, Connecticut $3.01B AUM 119.46% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
ACM
AIGH Capital Management Baltimore, Maryland $1.59B AUM 855.46% 1-Year Est. Return
Susquehanna International Group
Susquehanna International Group Bala Cynwyd, Pennsylvania $1.28T AUM 58.89% 1-Year Est. Return

Readystate Asset Management's ZVRA Position: Q3 2025 in Review

Readystate Asset Management sold out of Zevra Therapeutics (ZVRA) in Q3 2025, closing a stake of 111,515 shares — an estimated $982K sold.

Readystate Asset Management first reported a position in ZVRA in Q4 2024 and held it in 3 quarters. The position peaked at $5.12M in Q1 2025. 166 funds tracked by Wall St. Rank hold ZVRA as of Q3 2025.

  • Readystate Asset Management reported no remaining Zevra Therapeutics position as of Q3 2025 after selling out during the quarter.
  • Readystate Asset Management sold 111,515 Zevra Therapeutics shares in Q3 2025, an estimated $982K.
  • Readystate Asset Management first reported a position in Zevra Therapeutics in Q4 2024 and held it in 3 quarters.
  • Readystate Asset Management's Zevra Therapeutics position peaked at $5.12M in Q1 2025.
  • 166 funds tracked by Wall St. Rank held Zevra Therapeutics as of Q3 2025.

Based on Readystate Asset Management's 13F filing for Q3 2025, filed 7 Nov 2025.